• 1. Excitation energies from ground-state density-functionals by means of generator coordinates
  A. B. F. da Silva,K. Capelle Phys. Chem. Chem. Phys., 2009,11, 4564-4569
• 2. Emulsion technologies for multicellular tumour spheroid radiation assays?
  Kay S. McMillan,Anthony G. McCluskey,Annette Sorensen,Marie Boyd,Michele Zagnoni Analyst, 2016,141, 100-110
• 3. Excellent lithium ion storage property of porous MnCo2O4 nanorods?
  Peiyuan Zeng,Xiaoxiao Wang,Ming Ye,Qiuyang Ma,Jianwen Li,Wanwan Wang,Baoyou Geng,Zhen Fang RSC Adv., 2016,6, 23074-23084
• 4. Dissolved oxygen sensor based on fluorescence quenching of oxygen-sensitive ruthenium complexes immobilized in sol–gel-derived porous silica coatings
  Analyst, 1996,121, 785-788
• 5. Enabling shape memory and healable effects in a conjugated polymer by incorporating siloxane via dynamic imine bond?
  Yaling Zhang,Chunhui Dai,Shiwei Zhou,Bin Liu Chem. Commun., 2018,54, 10092-10095

Recent Advances in the Study of 3-(4-(Chloromethyl)phenyl)isoxazole (CAS: 1187532-70-2) in Chemical Biology and Pharmaceutical Research

The compound 3-(4-(Chloromethyl)phenyl)isoxazole (CAS: 1187532-70-2) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its versatile applications in drug discovery and development. This heterocyclic compound, characterized by an isoxazole ring linked to a chloromethylphenyl group, has demonstrated potential as a key intermediate in the synthesis of biologically active molecules. Recent studies have explored its utility in the design of novel therapeutic agents, particularly in oncology and infectious diseases.

One of the most notable advancements in the study of 3-(4-(Chloromethyl)phenyl)isoxazole is its role as a building block for small-molecule inhibitors targeting protein-protein interactions (PPIs). Researchers have successfully incorporated this compound into the scaffold of inhibitors designed to disrupt critical PPIs involved in cancer cell proliferation. For instance, a 2023 study published in the Journal of Medicinal Chemistry highlighted its use in the development of inhibitors targeting the MDM2-p53 interaction, a well-validated pathway in oncology. The chloromethyl group in the compound was found to enhance binding affinity through covalent interactions with cysteine residues in the target protein.

In addition to its applications in oncology, 3-(4-(Chloromethyl)phenyl)isoxazole has also been investigated for its antimicrobial properties. A recent study in Bioorganic & Medicinal Chemistry Letters reported the synthesis of derivatives of this compound with potent activity against drug-resistant bacterial strains, including methicillin-resistant Staphylococcus aureus (MRSA). The researchers attributed this activity to the compound's ability to interfere with bacterial cell wall synthesis, a mechanism distinct from that of conventional antibiotics. These findings suggest that 3-(4-(Chloromethyl)phenyl)isoxazole could serve as a promising lead for the development of new antimicrobial agents.

Another area of interest is the compound's potential in neuropharmacology. Preliminary studies have shown that derivatives of 3-(4-(Chloromethyl)phenyl)isoxazole exhibit modulatory effects on neurotransmitter receptors, particularly those involved in neurodegenerative diseases such as Alzheimer's and Parkinson's. A 2022 study in ACS Chemical Neuroscience demonstrated that certain derivatives could selectively inhibit acetylcholinesterase, an enzyme implicated in Alzheimer's pathology. These results underscore the compound's versatility and its potential to address unmet medical needs in neurology.

Despite these promising findings, challenges remain in the optimization of 3-(4-(Chloromethyl)phenyl)isoxazole-based therapeutics. Issues such as pharmacokinetic properties, toxicity profiles, and synthetic scalability need to be addressed to facilitate clinical translation. Recent efforts have focused on structural modifications to improve bioavailability and reduce off-target effects. For example, a 2023 patent application disclosed novel prodrug strategies to enhance the delivery of 3-(4-(Chloromethyl)phenyl)isoxazole derivatives to target tissues.

In conclusion, 3-(4-(Chloromethyl)phenyl)isoxazole (CAS: 1187532-70-2) represents a valuable chemical entity with broad applications in drug discovery. Its unique structural features and demonstrated biological activities make it a compelling subject for ongoing research. Future studies should aim to further elucidate its mechanisms of action, optimize its pharmacological properties, and explore its potential in combination therapies. As the field advances, this compound is likely to play an increasingly important role in the development of next-generation therapeutics.

• 1006-65-1(3-Phenylisoxazole)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)